Hilton Capital Management’s GSK GSK Stock Holding History

Hilton Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21,029	Closed	-$1.13M	–	124
2016 Q3	$1.13M	Buy	+21,029	New	+$1.15M	0.28%	55

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hilton Capital Management's GSK Position: Q4 2016 in Review

Hilton Capital Management sold out of GSK (GSK) in Q4 2016, closing a stake of 21,029 shares — an estimated $1.13M sold.

Hilton Capital Management first reported a position in GSK in Q3 2016 and held it in 1 quarter. The position peaked at $1.13M in Q3 2016. 762 funds tracked by Wall St. Rank hold GSK as of Q4 2016.

Hilton Capital Management reported no remaining GSK position as of Q4 2016 after selling out during the quarter.
Hilton Capital Management sold 21,029 GSK shares in Q4 2016, an estimated $1.13M.
Hilton Capital Management first reported a position in GSK in Q3 2016 and held it in 1 quarter.
Hilton Capital Management's GSK position peaked at $1.13M in Q3 2016.
762 funds tracked by Wall St. Rank held GSK as of Q4 2016.

Based on Hilton Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.